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Introduction: Differentiation of vascular endothelial cells (ECs) in clinically relevant numbers for injection into
ischaemic areas could offer therapeutic potential in the treatment of cardiovascular conditions, including
myocardial infarction, peripheral vascular disease and stroke. While we and others have demonstrated successful
generation of functional endothelial-like cells from human embryonic stem cells (hESCs), little is understood
regarding the complex transcriptional and epigenetic changes that occur during differentiation, in particular during
early commitment to a mesodermal lineage.
Methods: We performed the first gene expression microarray study of hESCs undergoing directed differentiation to
ECs using a monolayer-based, feeder-free and serum-free protocol. Microarray results were confirmed by
quantitative RT-PCR and immunocytochemistry, and chromatin immunoprecipitation (ChIP)-PCR analysis was utilised
to determine the bivalent status of differentially expressed genes.
Results: We identified 22 transcription factors specific to early mesoderm commitment. Among these factors,
FOXA2 was observed to be the most significantly differentially expressed at the hESC–EC day 2 timepoint. ChIP-PCR
analysis revealed that the FOXA2 transcription start site is bivalently marked with histone modifications for both
gene activation (H3K4me3) and repression (H3K27me3) in hESCs, suggesting the transcription factor may be a key
regulator of hESC differentiation.
Conclusion: This enhanced knowledge of the lineage commitment process will help improve the design of
directed differentiation protocols, increasing the yield of endothelial-like cells for regenerative medicine therapies in
cardiovascular disease.
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The directed differentiation of human embryonic stem
cells (hESCs) towards endothelial cell (EC) lineages of-
fers therapeutic potential in the treatment of myocardial
infarction, peripheral vascular disease and stroke [1].
While successful derivation of endothelial-like cells from
hESCs has been demonstrated [2-5], relatively little is
understood regarding early commitment to mesoderm
and subsequent specification [6].
To commit to a specified lineage, pluripotent cells must
undergo radical transcriptional change [2], partly regulated
by miRNAs [2,3]. Recent studies suggest epigenetic influ-
ences also play a significant role in the determination of
cell fate [7]. Indeed, the poised transcriptional state classic-
ally associated with pluripotent hESCs is maintained via ef-
fects at the chromatin level with gene expression
determined by post-translational modification of histones
[8]. While some histone marks, such as trimethylation of
lysine 4 of histone H3 (H3K4me3), are associated with
gene activation, others, such as trimethylation of lysine 27
of histone H3 (H3K27me3), are associated with repression.
However, around 3,000 developmental regulatory genes in
embryonic stem cells are labelled with both H3K4me3 and
H3K27me3 [7], allowing the genes to be rapidly activated
upon differentiation or to remain silenced during commit-
ment to lineages not requiring their expression. Unsurpris-
ingly, these bivalently marked genes are proposed to be
master regulators of the differentiation process, although
their role in endothelial differentiation has not been exten-
sively investigated to date.
The study described herein was designed to profile tran-
scriptional and epigenetic changes during early hESC com-
mitment to a mesodermal and endothelial-like fate with a
view to improving understanding of this process and to op-
timise the generation of ECs for regenerative medicine pur-
poses.
Methods
Cell culture
hESC lines SA461 (Cellartis, Dundee, UK), H1 and H9
(WiCell Research Institute, Madison, WI, USA) and RC10
(Roslin Cells Ltd, Edinburgh, UK) were cultured in a
monolayer-based, serum-free and feeder-free system.
Pluripotency was maintained and endothelial differenti-
ation induced as previously described [2]. Primary human
saphenous vein endothelial cells (HSVECs) were isolated
on the day of surgery by standard collagenase digestion
based on a modified version of the protocol described by
Jaffe and colleagues [9]. HSVECs were then cultured as
previously described [2]. All participants gave written in-
formed consent. The study was approved by the West of
Scotland Ethics Committee (06/S0703/110) and complies
with the principles of the Declaration of Helsinki.Microarray analysis
SA461 hESCs subjected to directed endothelial differenti-
ation were harvested at days 0, 2, 4 and 10, and RNA was
isolated using the miRNAeasy Mini Kit (Qiagen, Crawley,
UK). HSVEC RNA was harvested to act as a positive
control. Complementary RNA was prepared for hybridisa-
tion with Illumina® HT-12 v3 Expression BeadChip
microarrays (Illumina®, Saffron Walden, UK) and the gene
expression assessed. Microarray data were deposited in the
ArrayExpress public repository [ArrayExpress: E-MTAB-
1510]. Figure 1A outlines the experimental design.
Data were quantile normalised and background
subtracted in Genome Studio (Illumina®) and were then
exported to Partek® Genomics Suite™ (Partek® Inc., St.
Louis, MO, USA) and visualised using principle compo-
nent analysis [10]. An error-weighted analysis of variance
with a false discovery rate multiple testing adjustment
threshold of 0.05 was used to identify differentially
expressed probe sets [11], which were then uploaded to In-
genuity Pathway Analysis software (2009; Ingenuity® Sys-
tems, Redwood City, CA, USA) and analysed to identify
dynamic gene expression.
In silico prediction of bivalency
H3K27me3 and H3K4me3 data from the H9 chromatin
immunoprecipitation (ChIP)-sequencing dataset of Ku
and colleagues [12] were mined and integrated with
microarray data to give an in silico prediction of the bi-
valent status of genes.
SICER software (http://home.gwu.edu/~wpeng/Software.
htm) was used to determine enriched domains for each
histone modification using a stringent E value of 0.1, a win-
dow size of 200 and gap sizes of 200, 400, 600, 800 and
1,000 base pairs [13]. For each gene within the Ensembl
gene set (NCBI36.1), the transcription start site (TSS) was
determined and an interval spanning ±2 kb around the
TSS was defined.
For a specific gap size, if the TSS contained enriched
domains for both H3K27me3 and H3K4me3 marks, then
this gene was classified as bivalent. The bivalency score
was defined as the count of gap sizes where a gene was
considered bivalent. A score of 0 would thus indicate
that the gene was never classified as bivalent, while a
score of 5 indicated that the gene was found to be bi-
valent regardless of the gap size chosen.
TaqMan® quantitative RT-PCR
First-strand cDNA was synthesised from 1 μg DNase-
treated total RNA using TaqMan Reverse Transcription
Reagents (Applied Biosystems, Life Technologies Ltd.,
Paisley, UK). TaqMan® Gene Expression Assays for
CXXC1 (Hs00969406_g1), EHMT2 (Hs00938384_g1),
FOXA2 (Hs00232764_m1), L3MBTL2 (Hs01002038_g1),
MLL3 (Hs01005539_m1), RBM14 (Hs01056358_m1),
Figure 1 Illumina® (Saffron Walden, UK) whole genome expression microarray. (A) Study design with different timepoints under directed
human embryonic stem cell (hESC)–endothelial cell (EC) differentiation. Arrows represent pairwise comparisons performed. (B) Principle
component analysis (PCA) showing separation of primary mature human saphenous vein endothelial cells (HSVECs) and hESC-derived cells.
(C) Summary of differentially expressed probe sets. Numbers in brackets represent total number of differentially expressed probe sets for the
associated pairwise comparison.
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TSC22D3 (Hs00608272_m1), UBTF (Hs00610733_g1),
USF2 (Hs01100995_g1) and ZNF35 (Hs01071488_m1)
were used with TaqMan® Endogenous Controls, 18S
(Hs99999901_s1) or UBC (Hs00824723_m1) (Applied
Biosystems, Life Technologies). Relative quantitation of
gene expression was calculated using the comparative
(ΔΔCt) method [14].Immunocytofluorescence
Immunocytofluorescence experiments were carried out as
previously described [2]. Primary antibodies utilised were
mouse anti-OCT4 primary antibody (SC5279, 1:200; Santa
Cruz Biotechnology Inc., Dallas, TX, USA) and goat anti-
FOXA2 primary antibody (AF2400, 1:50; R&D Systems
Europe Ltd., Abingdon, UK). Secondary antibodies were
Alexafluor-488 donkey anti-goat (A11055; Invitrogen,
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555 goat anti-mouse (A21424; Invitrogen). ProLong
Gold with 4′,6-diamidino-2-phenylindole (Invitrogen)
was used for nuclear counterstaining.
Chromatin immunoprecipitation and PCR identification
ChIP assays were performed based on a modified version
of the method of Rai and colleagues [15]. Chromatin
was prepared from pluripotent H9s and SA461s, and
H3K4me3 and H3K27me3 were immunoprecipitated using
Dynabeads® M-280 sheep anti-rabbit IgG (Invitrogen) and
H3K4me3 (AB8580; Abcam, Cambridge, UK) and H3K27me3
(C36B11; Cell Signaling Technology, Beverly, MA, USA) spe-
cific antibodies. Immunoprecipitations with total H3 (AB1791;
Abcam) and control IgG (M7023; Sigma-Aldrich Company
Ltd., Dorset, UK) were included as positive and negative con-
trols, respectively.
Using the University of California Santa Cruz Genome
Browser, primer pairs were designed to span the FOXA2
TSS (Additional files 1, 2 and 3) and DyNAmo™ SYBR®
Green quantitative PCR (Thermo Fisher Scientific UKTable 1 Differentially expressed human embryonic stem cell–
Gene symbol Entrez gene nam
ANKRA2 Ankyrin repeat, family A (RF
ASCL2 Achaete-scute complex homolo
CXXC1 CXXC finger prote
DNMT3L DNA (cytosine-5)-methyltran
EHMT2 Euchromatic histone-lysine N-m
FOXA2 Forkhead box A
GABPB1 GA binding protein transcription fa
HDAC5 Histone deacetyla
L3MBTL2 l(3)mbt-like 2 (Droso
MLL3 Myeloid/lymphoid or mixed-lin
MNT MAX binding pro
RAX2 (human) Retina and anterior neural fol
RBM14 RNA binding motif pr
RFX1 (includes
EG:100038773)
Regulatory factor X, 1 (influences H
SNAPC4 Small nuclear RNA activating complex
SRA1 Steroid receptor RNA a
TAF6L TAF6-like RNA polymerase II, p300/CBP-asso
65 kDa
TFAP4 Transcription factor AP-4 (activating enh
TSC22D3 TSC22 domain family, m
UBTF Upstream binding transcription fact
USF2 Upstream transcription factor 2
ZNF35 Zinc finger protein
Fold change and false discovery rate (FDR) for the 22 differentially expressed genes
from 0 to 5: 0, not bivalently marked; 5, genes are robustly bivalent with enriched d
start site.Ltd., Loughborough, UK) was performed on immuno-
precipitation eluates, in addition to 2% chromatin input
not subjected to immunoprecipitation. Quantitative PCR
data were normalised to IgG negative control and
displayed as fold enrichment.Statistical analyses
Values are presented as mean ± standard error of the mean.
Data from multiple groups were analysed using repeated-
measures analysis of variance. Significant differences were
determined by Tukey post-hoc testing and P <0.05 (two-
tailed) was considered significant.Results
Gene expression analysis of endothelial differentiation
Principle component analysis of global transcription
data, designed to detect early transcriptional changes
during directed differentiation (Figure 1A), revealed suf-
ficient separation of cell groups. As expected, HSVECs
were clearly distinct from all hESC-derived cells, andendothelial cell day 2 transcription factor-encoding genes
e Fold
change
FDR Bivalency
score
XANK-like), 2 −1.64 0.01 0
g 2 (Drosophila) 1.24 0.05 5
in 1 1.82 0.02 0
sferase 3-like 1.29 0.01 0
ethyltransferase 2 1.46 0.02 0
2 1.51 <0.005 5
ctor, beta subunit 1 −1.47 0.02 0
se 5 1.21 0.03 0
phila) 1.37 0.03 0
eage leukemia 3 1.28 0.01 0
tein 1.50 0.02 0
d homeobox 2 1.57 0.04 0
otein 14 1.72 0.01 0
LA class II expression) 1.47 0.02 0
, polypeptide 4, 190 kDa 1.80 0.04 0
ctivator 1 1.34 0.01 0
ciated factor-associated factor, 1.75 0.01 0
ancer binding protein 4) 1.62 0.01 0
ember 3 −1.73 <0.005 5
or, RNA polymerase I 1.60 0.02 0
, c-fos interacting 1.73 0.04 0
35 1.33 0.02 0
are shown. In silico prediction of bivalency involved assigning bivalency scores
omains of H3K4me3 and H3K27me3 within 2 kb of their transcription
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with day 0 and day 2 timepoints (Figure 1B).
A large number of significantly differentially expressed
probe sets was observed at each of the three differentiation
timepoints, as compared with day 0 (Figure 1C). Compari-
son of samples from day 10 hESC–EC with HSVEC sam-
ples revealed differential expression of 6,133 different
probe-sets, defining markedly different cells (Figure 1C).
Further investigation of the hESC–EC day 2 timepoint
was carried out and 223 significantly differentially expressed,
unique probe sets were identified (Figure 1C). We reasoned
that corresponding genes might be involved in early differ-
entiation. The Ingenuity Pathway Analysis software revealed
that these probe sets correspond to 178 genes (Additional
file 4), a relatively high proportion (>12%) of which encode
for transcription factors (Table 1).Figure 2 Validation of human embryonic stem cell–endothelial cell da
mRNA expression of 12 of the 22 transcription factors was confirmed by Ta
was confirmed in H1s and RC10s by TaqMan® quantitative RT-PCR. *P <0.05
quantitation. (C) Immunocytofluorescent staining showing upregulation of
cell (hESC–SC) day 2. DAPI, 4′,6-diamidino-2-phenylindole; HSVEC, primary hTo validate this differential expression of transcription
factors, quantitative RT-PCR was performed. Of the 22
genes listed, 12 were confirmed as being differentially
expressed – including FOXA2, which demonstrated the
most significant and rapid upregulation of all genes exam-
ined (Figure 2A). Upregulation of FOXA2 at hESC–EC
day 2 was also confirmed in additional H1 and RC10
hESC lines (Figure 2B). Again, upregulation was transient
as analysis of day 4, day 7 and day 10 differentiations failed
to detect expression of FOXA2 mRNA (data not shown).
To confirm day 2 differential expression of FOXA2 at the
protein level, SA461s, H1s and RC10s were stained using
anti-FOXA2 antibodies. Expression of the pluripotency
marker OCT4 was observed in day 0 pluripotent cells but
diminished by hESC–EC day 2 (Figure 2C). FOXA2,
although present in a subset of pluripotent cells, wasy 2 transcription factor differential expression. (A) Differential
qMan® quantitative RT-PCR. (B) Differential expression of FOXA2 mRNA
, **P <0.01 and ***P <0.001 versus pluripotent control. RQ, relative
FOXA2 protein expression at human embryonic stem cell–endothelial
uman saphenous vein endothelial cell. Scale bars = 20 μm.
Figure 3 In vitro validation of predicted FOXA2 bivalency. Immunoprecipitation of H3K4me3, H3K27me3 and total H3 from chromatin of
pluripotent SA461s and H9s revealed enrichment of the histone modifications at the FOXA2 transcriptional start site, as identified by quantitative
PCR using primers for three regions, covering around 2.5 kb in total. *P <0.05 versus IgG control.
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did not co-localise with OCT4 (Figure 2C).
Epigenetic analysis of FOXA2
On aligning in silico data with differentially expressed
genes identified via microarray analysis, a large propor-
tion (2,684/3,883) achieved a bivalency score of 5 and
was therefore predicted to be bivalently marked.
With epigenetics known to influence cell fate, the pre-
dicted bivalent status of genes encoding hESC–EC day 2
differentially expressed transcription factors was of par-
ticular interest. FOXA2 was identified as having both
H3K4me3 and H3K27me3 modifications at its TSS
(Table 1) and ChIP-PCR confirmed bivalency of the
FOXA2 TSS in pluripotent H9s and SA461s (Figure 3).
Discussion
To the best of our knowledge, this study describes the
first global gene expression profiling of hESCs at inter-
mediate timepoints during their directed differentiation
to an endothelial-like lineage using a monolayer-based,
feeder-free and serum-free protocol. The study is also
the first to identify transcription factors potentially spe-
cific to early mesoderm commitment, including FOXA2
which we show to be bivalently marked at the TSS. In
addition, we report that cells at day 10 of the differenti-
ation process remain genetically distinct from mature
endothelial cells, supporting our previous findings that
this timepoint yields progenitor-type cells, capable of
further differentiation in vivo [2].
Rapid and transient FOXA2 mRNA upregulation was
identified and confirmed at the protein level, suggesting the
hepatocyte nuclear factor may represent a marker of early
mesoderm lineage commitment. A member of the forkhead
class of DNA binding proteins, FOXA2 has been shown to
bind and open compacted chromatin at histones H3 andH4 [16] and is one of the first transcription factors to bind
target genes on differentiation [17]. Traditionally endoderm
associated, FOXA2 has not, as far as we are aware, previ-
ously been linked to hESC–EC differentiation. However,
with cells used for microarray analyses likely to represent
a somewhat heterogeneous population containing precur-
sors for both endoderm and mesoderm germ layers
[18,19], further investigation utilising purified cell popula-
tions will be required to confirm the importance of
FOXA2 in early EC commitment.
Epigenetic control of transcription is now known to play
a major role in cell fate determination and, as stated, we
have identified the FOXA2 TSS as being bivalently marked
in pluripotent hESCs, displaying histone modifications as-
sociated with both gene activation and repression. Con-
ceivably, FOXA2 may therefore be a marker of early
mesoderm lineage commitment and a potential regulator
of hESC-EC commitment. Such enhanced knowledge of
the complex commitment process is likely to prove im-
portant for optimising the design and development of di-
rected endothelial differentiation protocols.
Conclusion
This study is the first to generate global gene expression
profiles for hESCs undergoing directed differentiation to
ECs using a monolayer-based, serum-free and feeder-
free system, and is the first to identify transcription fac-
tors, including FOXA2, likely to be specific for early
mesoderm lineage commitment.
Additional files
Additional file 1: A figure showing the University of California
Santa Cruz Genome Browser visualisation of H3K4me3 and
H3K27me3 ChIP sequencing performed on pluripotent H9 hESCs.
Genome browser output from FOXA2 genomic location showing
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http://stemcellres.com/content/4/2/36presence of H3K4me3 and H3K27me3 at the transcriptional start site.
Output is based on the pluripotent H9 hESC ChIP sequencing data of Ku
and colleagues [12].
Additional file 2: A figure showing the location of primer pairs
designed for FOXA2 ChIP-PCR. University of California Santa Cruz
Genome Browser output showing the genomic location of the optimised
primer pairs designed for the FOXA2 transcription start site.
Additional file 3: A table presenting the sequences of forward and
reverse primers used for FOXA2 ChIP-PCR.
Additional file 4: A table presenting the differentially expressed
genes identified on Ingenuity Pathway Analysis software of Partek®
Genomics Suite™ hESC–EC day 2 microarray data. Within the
hESC–EC day 2 specific dataset, Ingenuity Pathway Analysis software
identified 178 genes as being differentially expressed (P ≤0.05).
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